Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Email this article to a Colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to My Articles & Searches Download to citation manager Citing Articles via HighWire Citing Articles via Google Scholar Articles by Polsky, D. Articles by Glick, H. A. Search for Related Content PubMed Citation Articles by Polsky, D. Articles by Glick, H. A. Costs, Cost Analysis Atypical Neuroleptics Conventional Neuroleptics Schizophrenia Spectrum Disorders Related Article

Clinical Trial-Based Cost-Effectiveness Analyses of Antipsychotic Use

OBJECTIVE: Second-generation antipsychotics make up one of the fastest growing segments of the rapidly growing pharmaceutical sector. Given limited health care resources, assessment of the value for the cost of second-generation antipsychotics relative to first-generation antipsychotics is critical for resource-allocation decisions. METHOD: With a MEDLINE search, the authors identified eight studies (based on six randomized clinical trials) that analyzed the cost-effectiveness of second-generation antipsychotics relative to first-generation antipsychotics in individuals with schizophrenia disorders. The authors reviewed appropriate methods of measurement, analysis, and design of cost-effectiveness studies in randomized clinical trials and evaluated the validity of economic results derived from the studies in light of appropriate methods. RESULTS: The eight randomized clinical trial-based cost-effectiveness studies of antipsychotic medications faced a variety of threats to validity related to 1) measurement of costs, 2) measurement of effectiveness, 3) analysis of costs, 4) measurement of sampling uncertainty, 5) analysis of incomplete cost data, 6) minimizing loss to follow-up, and 7) threats to external validity. CONCLUSIONS: Economic claims made by the authors of a number of trial-based economic evaluations have generally been favorable to second-generation antipsychotics. However, the methodological issues the authors of the current study identified suggest that there is no clear evidence that atypical antipsychotics generate cost savings or are cost-effective in general use among all schizophrenia patients. Psychiatrists, researchers, and administrators should consider the methodological issues highlighted in interpreting study results. These issues should be addressed in future trial designs.

Related Article:

In This Issue
Am J Psychiatry 2006 163: A68. [Full Text] [PDF]

This article has been cited by other articles:

				J. Parks, A. Radke, G. Parker, M.-E. Foti, R. Eilers, M. Diamond, D. Svendsen, and R. Tandon Principles of Antipsychotic Prescribing for Policy Makers, Circa 2008. Translating Knowledge to Promote Individualized Treatment Schizophr Bull, September 1, 2009; 35(5): 931 - 936. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck and M. J. Sernyak Developing A Policy For Second-Generation Antipsychotic Drugs Health Aff., September 1, 2009; 28(5): w782 - w793. [Abstract] [Full Text] [PDF]

				M. E. Domino and M. S. Swartz Who Are the New Users of Antipsychotic Medications? Psychiatr Serv, May 1, 2008; 59(5): 507 - 514. [Abstract] [Full Text] [PDF]

				R. A. Rosenheck, D. L. Leslie, and J. A. Doshi Second-Generation Antipsychotics: Cost-Effectiveness, Policy Options, and Political Decision Making Psychiatr Serv, May 1, 2008; 59(5): 515 - 520. [Abstract] [Full Text] [PDF]

				R.A. Rosenheck, D.L. Leslie, S. Busch, E. S. Rofman, and M. Sernyak Rethinking Antipsychotic Formulary Policy Schizophr Bull, March 1, 2008; 34(2): 375 - 380. [Abstract] [Full Text] [PDF]

				D. C. Owens How CATIE brought us back to Kansas: a critical re-evaluation of the concept of atypical antipsychotics and their place in the treatment of schizophrenia Adv. Psychiatr. Treat., January 1, 2008; 14(1): 17 - 28. [Abstract] [Full Text] [PDF]

				C. C. Denny, E. J. Emanuel, and S. D. Pearson Why Well-Insured Patients Should Demand Value-Based Insurance Benefits JAMA, June 13, 2007; 297(22): 2515 - 2518. [Full Text] [PDF]

				J. C. West, J. E. Wilk, I. L. Muszynski, D. S. Rae, M. Rubio-Stipec, C. L. Alter, W. E. Narrow, and D. A. Regier Medication Access and Continuity: The Experiences of Dual-Eligible Psychiatric Patients During the First 4 Months of the Medicare Prescription Drug Benefit Am J Psychiatry, May 1, 2007; 164(5): 789 - 796. [Abstract] [Full Text] [PDF]

				R. ROSENHECK, T. S. STROUP, M. SWARTZ, J. McEVOY, S. M. DAVIS, R. S.E. KEEFE, J. K. HSIAO, and J. LIEBERMAN Dr. Rosenheck and Colleagues Reply Am J Psychiatry, April 1, 2007; 164(4): 678 - 680. [Full Text] [PDF]

				Reviews of Note Journal Watch Psychiatry, January 22, 2007; 2007(122): 3 - 3. [Full Text]

Get information about faster international access.

Privacy Policy

Copyright © 2006 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us